Supplementation of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to Improve Insulin-Like Growth Factor-1 Function

What Was Tested

The paper reports a study of IGF-1 LR3, published as a clinical trial.

Insulin-like growth factor-1 (IGF-1) function is impaired in Parkinson disease.

The researchers evaluated the changes of cGP and IGF-1 before and after the supplementation.

Who Took Part

According to the abstract, 11 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, men only.

Plasma and cerebrospinal fluid (CSF) were collected from 11 male patients before and after 28 day supplementation of BCA.

How the Study Was Run

The methods mention a period of 28 days.

The concentrations of IGF-1, IGF binding protein (IGFBP)-3, and cGP were measured using ELISA and HPLC-MS assays.

The presence of cGP in the BCA was evaluated.

What Was Measured

The researchers evaluated the changes of cGP and IGF-1 before and after the supplementation.

PubMed files the paper under topics including Anthocyanins, Antiparkinson Agents, Biomarkers, Fruit, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Parkinson Disease.

The authors tagged it with the keywords autocrine regulation, bioavailability of insulin-like growth factor-1 (IGF-1), blackcurrant anthocyanins, central uptake, cerebrospinal fluid and cyclic Glycine-Proline (cGP).

What This Means in Plain Language

This is a clinical trial of IGF-1 LR3 in 11 patients over 28 days.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Nutrients), a journal based in Switzerland.

More context: the IGF-1 LR3 compound page, all human trials.